Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Inotuzumab Ozogamicin and Blinatumomab with Standard Chemotherapy in Treating Newly Diagnosed Patients with B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Trial Status: active

This phase II trial studies how well adding inotuzumab ozogamicin and blinatumomab to standard chemotherapy works in treating patients with B-cell precursor acute lymphoblastic leukemia and lymphoma. Inotuzumab ozogamicin is a monoclonal antibody called inotuzumab linked to a drug called ozogamicin. It is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22, and delivers ozogamicin to kill them. Bispecific antibodies such as blinatumomab connect a part of the patient's immune system called T-cells to cancer cells and help the immune system kill the cancer cell. Blinatumomab targets cancer cells through a specific molecule called CD19. Standard chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding inotuzumab ozogamicin and blinatumomab to standard chemotherapy may be better at getting rid of leukemia in the blood and bone marrow than giving standard chemotherapy alone.